These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
286 related articles for article (PubMed ID: 31391510)
21. Identification of a monoclonal antibody that targets PD-1 in a manner requiring PD-1 Asn58 glycosylation. Wang M; Wang J; Wang R; Jiao S; Wang S; Zhang J; Zhang M Commun Biol; 2019; 2():392. PubMed ID: 31667366 [TBL] [Abstract][Full Text] [Related]
22. Emerging Role of Immunotherapy in Advanced Urothelial Carcinoma. Koshkin VS; Grivas P Curr Oncol Rep; 2018 Apr; 20(6):48. PubMed ID: 29644490 [TBL] [Abstract][Full Text] [Related]
23. Comparison of PD-L1 immunohistochemistry assays and response to PD-1/L1 inhibitors in advanced non-small-cell lung cancer in clinical practice. Villaruz LC; Ancevski Hunter K; Kurland BF; Abberbock S; Herbst C; Dacic S Histopathology; 2019 Jan; 74(2):269-275. PubMed ID: 30105871 [TBL] [Abstract][Full Text] [Related]
24. Anti-PD-1 and Anti-PD-L1 in Head and Neck Cancer: A Network Meta-Analysis. Botticelli A; Cirillo A; Strigari L; Valentini F; Cerbelli B; Scagnoli S; Cerbelli E; Zizzari IG; Rocca CD; D'Amati G; Polimeni A; Nuti M; Merlano MC; Mezi S; Marchetti P Front Immunol; 2021; 12():705096. PubMed ID: 34434192 [TBL] [Abstract][Full Text] [Related]
25. First-Line Treatment of Non-Small-Cell Lung Cancer (NSCLC) with Immune Checkpoint Inhibitors. Bylicki O; Barazzutti H; Paleiron N; Margery J; Assié JB; Chouaïd C BioDrugs; 2019 Apr; 33(2):159-171. PubMed ID: 30825132 [TBL] [Abstract][Full Text] [Related]
26. The Targeting Effect of Cetuximab Combined with PD-L1 Blockade against EGFR-Expressing Tumors in a Tailored CD16-CAR T-Cell Reporter System. Li Y; Gao Q; Liu H; Lin S; Chen H; Ding R; Gu Y; Chao CC; Dong X Cancer Invest; 2021 Apr; 39(4):285-296. PubMed ID: 33646061 [TBL] [Abstract][Full Text] [Related]
27. Overcoming Primary Resistance to PD-1 Inhibitor With Anti-PD-L1 Agent in Squamous-Cell NSCLC: Case Report. Gelsomino F; Di Federico A; Filippini DM; Dall'Olio FG; Lamberti G; Sperandi F; Balacchi C; Brocchi S; Ardizzoni A Clin Lung Cancer; 2020 Mar; 21(2):e45-e48. PubMed ID: 31902695 [No Abstract] [Full Text] [Related]
28. Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis. Shen X; Zhao B BMJ; 2018 Sep; 362():k3529. PubMed ID: 30201790 [TBL] [Abstract][Full Text] [Related]
29. Real-world outcomes of anti-PD1 antibodies in platinum-refractory, PD-L1-positive recurrent and/or metastatic non-small cell lung cancer, and its potential practical predictors: first report from Korean Cancer Study Group LU19-05. Park JH; You GL; Ahn MJ; Kim SW; Hong MH; Han JY; Ock CY; Lee JS; Oh IJ; Lee SY; Kim CH; Min YJ; Choi YH; Ryu JS; Park SH; Ahn HK; Shim BY; Lee KH; Lee SY; Kim JS; Yi J; Choi SK; An H; Kang JH J Cancer Res Clin Oncol; 2021 Aug; 147(8):2459-2469. PubMed ID: 33523301 [TBL] [Abstract][Full Text] [Related]
30. [Efficacy of PD-1/PD-L1 immune checkpoint inhibitors and PD-L1 testing in thoracic cancers]. Duruisseaux M; Rouquette I; Adam J; Cortot A; Cazes A; Gibault L; Damotte D; Lantuejoul S Ann Pathol; 2017 Feb; 37(1):61-78. PubMed ID: 28162296 [TBL] [Abstract][Full Text] [Related]
31. A review on the evolution of PD-1/PD-L1 immunotherapy for bladder cancer: The future is now. Bellmunt J; Powles T; Vogelzang NJ Cancer Treat Rev; 2017 Mar; 54():58-67. PubMed ID: 28214651 [TBL] [Abstract][Full Text] [Related]
32. Which is the optimal immunotherapy for advanced squamous non-small-cell lung cancer in combination with chemotherapy: anti-PD-1 or anti-PD-L1? Zhang Y; Zhou H; Zhang L J Immunother Cancer; 2018 Dec; 6(1):135. PubMed ID: 30509312 [TBL] [Abstract][Full Text] [Related]
33. Blocking PD-1/PD-L1 by an ADCC enhanced anti-B7-H3/PD-1 fusion protein engages immune activation and cytotoxicity. Xu Y; Xiao Y; Luo C; Liu Q; Wei A; Yang Y; Zhao L; Wang Y Int Immunopharmacol; 2020 Jul; 84():106584. PubMed ID: 32422527 [TBL] [Abstract][Full Text] [Related]
35. Characterization of dermatitis after PD-1/PD-L1 inhibitor therapy and association with multiple oncologic outcomes: A retrospective case-control study. Min Lee CK; Li S; Tran DC; Zhu GA; Kim J; Kwong BY; Chang ALS J Am Acad Dermatol; 2018 Dec; 79(6):1047-1052. PubMed ID: 29857011 [TBL] [Abstract][Full Text] [Related]
36. PD-1-PD-L1 immune-checkpoint blockade in malignant lymphomas. Wang Y; Wu L; Tian C; Zhang Y Ann Hematol; 2018 Feb; 97(2):229-237. PubMed ID: 29128997 [TBL] [Abstract][Full Text] [Related]
37. The effects of checkpoint inhibition on head and neck squamous cell carcinoma: A systematic review. Ghanizada M; Jakobsen KK; Grønhøj C; von Buchwald C Oral Oncol; 2019 Mar; 90():67-73. PubMed ID: 30846179 [TBL] [Abstract][Full Text] [Related]
38. PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations. Jiang Y; Chen M; Nie H; Yuan Y Hum Vaccin Immunother; 2019; 15(5):1111-1122. PubMed ID: 30888929 [TBL] [Abstract][Full Text] [Related]
39. Is it possible to rechallenge with PD-1/PD-L1 inhibitors after progression? Saleh K; Khalifeh-Saleh N; Kourie HR Immunotherapy; 2018 Apr; 10(5):345-347. PubMed ID: 29473468 [No Abstract] [Full Text] [Related]